Optimizing Venetoclax Dosing and Treatment Duration with Azacitidine in Acute Myeloid Leukemia: Evidence, Limitations, and Personalized Strategies

Venetoclax combined with azacitidine has transformed the treatment of newly diagnosed acute myeloid leukemia in patients ineligible for intensive chemotherapy. However, prolonged cytopenias, infectious complications, and treatment interruptions have prompted increasing use of abbreviated venetoclax schedules. This narrative review critically examines the evidence supporting modifications in treatment duration and daily dose, with emphasis on the balance between antileukemic efficacy and tolerability. Retrospective studies, including the analysis by Willekens and colleagues, suggest that shorter schedules may reduce selected measures of hematologic toxicity and supportive-care burden while maintaining encouraging remission rates. Nevertheless, these findings are vulnerable to selection bias and cannot establish equivalence. Importantly, the randomized OPTI-AML trial did not demonstrate noninferiority of a 14-day induction schedule compared with 28 days and identified a potentially relevant reduction in early complete remission among patients harboring NPM1 and/or IDH2 mutations. These observations suggest that the consequences of shortening venetoclax exposure may depend on treatment phase and leukemia biology. We discuss pharmacokinetic interactions, post-remission cytopenia management, and molecularly informed treatment adaptation, and highlight the need for prospective studies that jointly evaluate efficacy, toxicity, and patient-centered outcomes.

Authors

Institutions

Publication Details

Journal
Cancers
Published
2026-11-13
DOI
https://doi.org/10.3390/cancers18223625
Primary Topic
Acute Myeloid Leukemia Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Optimizing Venetoclax Dosing and Treatment Duration with Azacitidine in Acute Myeloid Leukemia: Evidence, Limitations, and Personalized Strategies

Matteo Molica, Giulio Caridà, Marco Rossi, Laura De Fazio et al.
6 links
Cancers
Acute Myeloid Leukemia Research
article

Optimizing Venetoclax Dosing and Treatment Duration with Azacitidine in Acute Myeloid Leukemia: Evidence, Limitations, and Personalized Strategies

Matteo Molica, Giulio Caridà, Marco Rossi, Laura De Fazio, Massimo Vincenzo Martino, Ferdinando Porretto, Antonino Mulè, Caterina Alati, Martina Costa
article en

Abstract

Venetoclax combined with azacitidine has transformed the treatment of newly diagnosed acute myeloid leukemia in patients ineligible for intensive chemotherapy. However, prolonged cytopenias, infectious complications, and treatment interruptions have prompted increasing use of abbreviated venetoclax schedules. This narrative review critically examines the evidence supporting modifications in treatment duration and daily dose, with emphasis on the balance between antileukemic efficacy and tolerability. Retrospective studies, including the analysis by Willekens and colleagues, suggest that shorter schedules may reduce selected measures of hematologic toxicity and supportive-care burden while maintaining encouraging remission rates. Nevertheless, these findings are vulnerable to selection bias and cannot establish equivalence. Importantly, the randomized OPTI-AML trial did not demonstrate noninferiority of a 14-day induction schedule compared with 28 days and identified a potentially relevant reduction in early complete remission among patients harboring NPM1 and/or IDH2 mutations. These observations suggest that the consequences of shortening venetoclax exposure may depend on treatment phase and leukemia biology. We discuss pharmacokinetic interactions, post-remission cytopenia management, and molecularly informed treatment adaptation, and highlight the need for prospective studies that jointly evaluate efficacy, toxicity, and patient-centered outcomes.

CancersVol. 18(22)
Azienda ospedaliera "Bianchi-Melacrino-Morelli" (IT), Ospedale Vincenzo Cervello (IT), Azienda Ospedaliero-Universitaria "Renato Dulbecco" (IT), La Maddalena (IT)
Good health and well-being
Acute Myeloid Leukemia Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon